Dr. Agresta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
88 Sidney
Cambridge
Lexington, MA 02420Phone+1 813-745-5768- Is this information wrong?
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2003 - 2006
Tulane UniversityResidency, Internal Medicine, 1999 - 2003- Tulane University School of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2006 - 2012
Clinical Trials
- A Phase I Study of AG-348 in Healthy Volunteers Start of enrollment: 2014 Mar 01
- A Phase I Study of AG-348 in Healthy Volunteers Start of enrollment: 2014 May 01
- Food Effect Study of AG-221 in Healthy Male Subjects Start of enrollment: 2014 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 13 citationsClinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutationBin Fan, David Dai, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Eyal C. Attar, Hua Liu, Guowen Liu, Ian R Lemieux, Samuel V. Agresta, Hua Yang> ;Cancer Chemotherapy and Pharmacology. 2020 Apr 15
- 23 citationsEffect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.David Dai, Hua Yang, Salah Nabhan, Hua Liu, Denice Hickman, Guowen Liu, Jeffrey Zacher, Apinya Vutikullird, Chandra Prakash, Samuel V. Agresta, Chris Bowden, Bin Fan> ;European Journal of Clinical Pharmacology. 2019 Apr 23
- 146 citationsEnasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaDaniel A. Pollyea, Martin S. Tallman, Stéphane de Botton, Hagop M. Kantarjian, Robert H. Collins, Anthony S. Stein, Mark G. Frattini, Qiang Xu, Alessandra Tosolini, We...> ;Leukemia. 2019 Nov 1
- Join now to see all
Press Mentions
Therapeutics Expands Leadership Team with Two C-suite AppointmentsSeptember 16th, 2019- Infinity Pharmaceuticals Announces Transition of Samuel Agresta, M.D., from Chief Medical Officer to Board of DirectorsAugust 22nd, 2019
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Summary as of Dec 18, 2018December 18th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
